Insmed Incorporated (INSM) : Palo Alto Investors scooped up 36,585 additional shares in Insmed Incorporated during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 5,091,298 shares of Insmed Incorporated which is valued at $76,929,513.Insmed Incorporated makes up approximately 4.48% of Palo Alto Investors’s portfolio.
Other Hedge Funds, Including , Point72 Asset Management sold out all of its stake in INSM during the most recent quarter. The investment firm sold 201,354 shares of INSM which is valued $3,042,459.Princeton Alpha Management Lp boosted its stake in INSM in the latest quarter, The investment management firm added 5,638 additional shares and now holds a total of 15,713 shares of Insmed Incorporated which is valued at $223,282. Insmed Incorporated makes up approx 0.04% of Princeton Alpha Management Lp’s portfolio. Teacher Retirement System Of Texas sold out all of its stake in INSM during the most recent quarter. The investment firm sold 8,286 shares of INSM which is valued $92,886.California Public Employees Retirement System reduced its stake in INSM by selling 5,900 shares or 6.41% in the most recent quarter. The Hedge Fund company now holds 86,200 shares of INSM which is valued at $1,212,834.
Insmed Incorporated closed down -0.16 points or -1.08% at $14.68 with 3,40,847 shares getting traded on Monday. Post opening the session at $14.9, the shares hit an intraday low of $14.29 and an intraday high of $14.9 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients with serious lung diseases. The Company’s product candidate ARIKAYCE or liposomal amikacin for inhalation (LAI) is being developed for at least two identified orphan patient populations: patients with non-tuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pseudomonas) lung infections. It is also focused on the development of INS1009 an inhaled treprostinil prodrug. Treprostinil is a prostacyclin used in the treatment of pulmonary arterial hypertension (PAH) a chronic life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. It has conducted a Phase II clinical trial in the United States and Canada of ARIKAYCE in patients who had treatment-resistant lung infections caused by NTM.